[HTML][HTML] Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
M De Laurentiis, G Cancello, D D'Agostino… - Database of Abstracts …, 2008 - ncbi.nlm.nih.gov
This review evaluated whether adding taxanes to anthracycline-based chemotherapy regimens
improves survival in women with early breast cancer. The authors found that addition of …
improves survival in women with early breast cancer. The authors found that addition of …
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
…, F Ciardiello, G Tortora, D D'Agostino… - Clinical cancer …, 2005 - AACR
Purpose: Experimental data suggest a complex cross-talk between HER-2 and estrogen
receptor, and it has been hypothesized that HER-2-positive tumors may be less responsive to …
receptor, and it has been hypothesized that HER-2-positive tumors may be less responsive to …
A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial
…, L Szenborn, W Daly, T Jackowska, D D'Agostino… - Vaccine, 2015 - Elsevier
Background A meningococcal vaccine protective against all major disease-associated
serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer-blinded, …
serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer-blinded, …
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma
BACKGROUND AND AIM: Prevalence of HCV infection in non-Hodgkin’s lymphoma is high.
The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a …
The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a …
[HTML][HTML] Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
…, A Gupta, M Ferguson, D D'Agostino, D Toneatto… - Vaccine, 2019 - Elsevier
Background Data on duration of protection against invasive meningococcal disease post-vaccination
with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB…
with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB…
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
G Cancello, E Montagna, D D'Agostino… - Breast Cancer …, 2008 - Springer
Introduction We performed a retrospective analysis of HER2-overexpressing metastatic
breast cancer patients to describe clinical outcomes of those who, despite progression of the …
breast cancer patients to describe clinical outcomes of those who, despite progression of the …
Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function
…, LM Yu, D D'Agostino, M Calabresi, D Toneatto… - …, 2018 - publications.aap.org
BACKGROUND: The capsular group B meningococcal vaccine (4CMenB) is recommended
for children with complement deficiencies, asplenia, and splenic dysfunction; however, data …
for children with complement deficiencies, asplenia, and splenic dysfunction; however, data …
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
…, S Kelly, H Robinson, LM Yu, D Toneatto, D D'Agostino… - Cmaj, 2015 - Can Med Assoc
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces
antibodies against indicator strains of serogroup B meningococcus under various schedules. …
antibodies against indicator strains of serogroup B meningococcus under various schedules. …
[HTML][HTML] Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers
…, G Zoppi, M de Martino, A Tasciotti, D D'Agostino… - Vaccine, 2016 - Elsevier
Background MenACWY-CRM (Menveo ® ; GlaxoSmithKline) and MenACWY-TT (Nimenrix
® ; Pfizer) are two meningococcal vaccines licensed in the European Union for use in both …
® ; Pfizer) are two meningococcal vaccines licensed in the European Union for use in both …
Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 …
…, D D'Agostino, I Smolenov, D Toneatto… - The Pediatric …, 2018 - journals.lww.com
Background: Current meningococcal prime-boost vaccination schedules include separate
vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY …
vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY …
